Shares of AXT Inc. surged 10.1% to $89.85 as investors digested a blowout second quarter that transformed the once-obscure semiconductor substrate maker into one of the hottest AI-infrastructure plays of 2026. The question now: whether the stock's 457% year-to-date climb has already priced in what's ahead — or whether a massive capacity buildout can keep earnings compounding.
• A Quarter That Wasn't Even Close to Estimates. Revenue hit $47.6 million — the highest in company history — up 77% sequentially and **164% year over year.
Adjusted earnings of $0.19 per share beat the Street's $0.07 estimate by 171%.
Indium phosphide revenue alone reached $30.7 million, also a company record — meaning a single product line now drives roughly two-thirds of the top line. Gross margins expanded to 45%, up from just 8.2% a year ago , a swing driven by volume, better product mix, and fixed costs being spread over far more wafers.
• Locked-In Customers Are Funding the Expansion. AXT signed long-term supply deals with Coherent and Lumentum that include prepayments of $22.3 million and $25.4 million , and the Lumentum pact alone locks in production through 2031, with two prepayments totaling $87 million. These upfront payments essentially let customers finance AXT's factory buildout — reducing dilution risk for shareholders while locking in years of guaranteed demand.
• The Guidance Gap Tells the Real Story. AXT guided Q3 revenue to roughly $66 million, nearly 70% above the $38.7 million Wall Street had modeled.
Projected Q3 earnings of $0.30–$0.32 per share more than triple the prior $0.10 consensus. That gap suggests analysts are still catching up with the pace of AI data-center optical spending.
• China Export Permits Remain the Wildcard. Export-permit timing remains a variable management cannot precisely predict.
The company's dependence on Chinese permits and rising China exposure are the principal risks. A single delayed approval could shift tens of millions in revenue between quarters, making the earnings trajectory lumpier than the headline numbers suggest.
Needham upgraded AXT to Buy on July 31 with a $90 price target — a level the stock is already testing. With a backlog exceeding $100 million and quarterly indium phosphide capacity targeted at $130 million by end of 2027 , the growth runway is real. But at these levels, flawless execution isn't optional — it's expected.